Related Experiment Video
Updated: Jun 27, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Association Between SGLT2 Inhibitor Use and New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve
Mustafa Ferhat Keten1, Kadir Biyikli1, Barkin Kultursay2
1Department of Cardiology, Hamidiye School of Medicine, Kosuyolu Heart, Education and Research Institute, University of Health Sciences, Istanbul 34925, Türkiye.
Journal of Clinical Medicine
|June 26, 2026
Summary
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with reduced new-onset atrial fibrillation (NOAF) after transcatheter aortic valve implantation (TAVI). This observational study suggests a protective effect, warranting further investigation in randomized trials.
Area of Science:
- Cardiology
- Pharmacology
- Medical Devices
Background:
- New-onset atrial fibrillation (NOAF) is a frequent complication post-transcatheter aortic valve implantation (TAVI).
- NOAF after TAVI is linked to adverse clinical outcomes.
- The potential antiarrhythmic effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in this context are not well-established.
Purpose of the Study:
- To investigate the association between SGLT2 inhibitor use and the incidence of NOAF following TAVI.
- To evaluate the safety and efficacy of SGLT2 inhibitors in patients undergoing TAVI.
Main Methods:
- Retrospective observational study of 573 patients undergoing transfemoral TAVI.
- Exclusion of patients with pre-existing atrial fibrillation or flutter.
- Doubly robust inverse probability weighted logistic regression to assess the association between SGLT2 inhibitor use and NOAF.
Main Results:
- SGLT2 inhibitor use was associated with a lower incidence of NOAF (11% vs. 19%, p=0.041).
- Adjusted analysis revealed SGLT2 inhibitor use was independently linked to reduced odds of NOAF (aOR: 0.171, p<0.001).
- Older age and diabetes mellitus increased NOAF risk, while higher LVEF decreased it.
Conclusions:
- SGLT2 inhibitor use demonstrates an independent association with lower odds of NOAF after TAVI.
- Findings are observational and hypothesis-generating.
- Prospective randomized studies are required for confirmation.
